Innoviva (INVA) EPS (Weighted Average and Diluted) (2010 - 2026)
Innoviva posted quarterly EPS (Weighted Average and Diluted) of $2.22 for Q1 2026, up 400.0% year-on-year from $0.44 in Q1 2025, and up 105.56% on a QoQ basis from $1.08 in Q3 2025.
Innoviva (INVA) has 16 years of EPS (Weighted Average and Diluted) data on file, last reported at $2.22 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 400.0% year-over-year to $2.22; the trailing twelve-month figure through Mar 2026 stood at $3.33 (up 511.11% YoY), and the FY2025 full-year result was $3.3, up 816.67% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $2.22, up from $1.08 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $2.8 in Q3 2022 and bottomed at -$0.74 in Q1 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is $0.42 (2023), against an average of $0.59.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) plunged 2850.0%; it then jumped 5300.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.8 in 2022, then slumped by 65.0% to $0.98 in 2023, then sank by 97.96% to $0.02 in 2024, then surged by 5300.0% to $1.08 in 2025, then surged by 105.56% to $2.22 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $2.22 (Q1 2026), $1.08 (Q3 2025), and $0.77 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 2.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.22 |
| Sep 30, 2025 | 1.08 |
| Jun 30, 2025 | 0.77 |
| Mar 31, 2025 | -0.74 |
| Sep 30, 2024 | 0.02 |
| Jun 30, 2024 | -0.55 |
| Mar 31, 2024 | 0.46 |
| Sep 30, 2023 | 0.98 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.42 |
| Sep 30, 2022 | 2.80 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | 0.20 |
| Sep 30, 2021 | 0.90 |
| Jun 30, 2021 | 0.90 |
| Mar 31, 2021 | 0.84 |
| Dec 31, 2020 | 0.49 |
| Sep 30, 2020 | 0.26 |
| Jun 30, 2020 | 0.69 |
| Mar 31, 2020 | 0.59 |
| Dec 31, 2019 | 0.42 |
| Sep 30, 2019 | 0.36 |
| Jun 30, 2019 | 0.34 |
| Mar 31, 2019 | 0.31 |
| Dec 31, 2018 | 2.34 |
| Sep 30, 2018 | 0.43 |
| Jun 30, 2018 | 0.49 |
| Mar 31, 2018 | 0.27 |
| Dec 31, 2017 | 0.50 |
| Sep 30, 2017 | 0.21 |
| Jun 30, 2017 | 0.30 |
| Mar 31, 2017 | 0.15 |
| Dec 31, 2016 | 0.22 |
| Sep 30, 2016 | 0.13 |
| Jun 30, 2016 | 0.13 |
| Mar 31, 2016 | 0.04 |
| Dec 31, 2015 | 0.04 |
| Sep 30, 2015 | -0.04 |
| Sep 30, 2013 | -0.44 |
| Jun 30, 2013 | -0.37 |
| Mar 31, 2013 | -0.39 |
| Sep 30, 2012 | -0.37 |
| Jun 30, 2012 | -0.42 |
| Mar 31, 2012 | 0.93 |
| Dec 31, 2011 | -0.45 |
| Sep 30, 2011 | -0.37 |
| Jun 30, 2011 | -0.31 |
| Mar 31, 2011 | -0.28 |
| Dec 31, 2010 | -0.27 |
| Sep 30, 2010 | -0.30 |
| Jun 30, 2010 | -0.28 |